Briggs Morrison Net Worth

The estimated Net Worth of Briggs Morrison is at least $7.49 million dollars as of 9 August 2023. Briggs Morrison owns over 52,855 units of Syndax Pharmaceuticals Inc stock worth over $1,295,059 and over the last 8 years he sold SNDX stock worth over $4,587,454. In addition, he makes $1,612,000 as Chief Executive Officer et Director at Syndax Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Briggs Morrison SNDX stock SEC Form 4 insiders trading

Briggs has made over 23 trades of the Syndax Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 52,855 units of SNDX stock worth $463,538 on 9 August 2023.

The largest trade he's ever made was exercising 279,420 units of Syndax Pharmaceuticals Inc stock on 14 September 2022 worth over $2,207,418. On average, Briggs trades about 29,084 units every 35 days since 2017. As of 9 August 2023 he still owns at least 70,691 units of Syndax Pharmaceuticals Inc stock.

You can see the complete history of Briggs Morrison stock trades at the bottom of the page.

Briggs Morrison biography

Dr. Briggs W. Morrison M.D. serves as Chief Executive Officer, Director of the Company. Dr. Morrison is a Class III director who has served as our Chief Executive Officer since June 2015 and as a member of our board of directors since July 2015. Dr. Morrison currently serves as a managing director of MPM Capital, a healthcare-focused venture capital firm, since June 2015. Prior to joining us, he served as Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca plc, a publicly traded pharmaceutical and biopharmaceutical company, from January 2012 to June 2015, leading the company’s global, late-stage development organization and serving as a member of the AstraZeneca senior executive team. He previously held a number of positions at Pfizer Inc., a publicly traded company, culminating in his appointment as Head, Medical Affairs, Safety and Regulatory Affairs for Pfizer’s human health business, and also served in roles of increasing responsibility at Merck Research Laboratories, a division of Merck & Co., Inc., ascending to the role of Vice President, Clinical Sciences, Oncology, responsible for clinical development of all novel anti-cancer drugs. Dr. Morrison was chairman of the board of TransCelerate BioPharma Inc., an industry-funded company charged with improving aspects of clinical trials, from 2014 to 2015, a member of the executive committee of the Clinical Trials Transformation Initiative sponsored by FDA, and is on the board of the Alliance for Clinical Research Excellence and Safety, Arvinas, Inc, a publicly traded company, as well as the boards of a number of private companies. Dr. Morrison received a B.S. in biology from Georgetown University and an M.D. from the University of Connecticut. Morrison’s experience as an executive officer of other successful companies in the pharmaceutical industry gives him the qualifications, skills and financial expertise to serve on our board of director.

What is the salary of Briggs Morrison?

As the Chief Executive Officer et Director of Syndax Pharmaceuticals Inc, the total compensation of Briggs Morrison at Syndax Pharmaceuticals Inc is $1,612,000. There are 1 executives at Syndax Pharmaceuticals Inc getting paid more, with Michael Metzger having the highest compensation of $2,696,890.

How old is Briggs Morrison?

Briggs Morrison is 61, he's been the Chief Executive Officer et Director of Syndax Pharmaceuticals Inc since 2015. There are 4 older and 12 younger executives at Syndax Pharmaceuticals Inc. The oldest executive at Syndax Pharmaceuticals Inc is Dr. Michael L. Meyers M.D., Ph.D., 70, who is the Chief Medical Officer & Sr. VP.

What's Briggs Morrison's mailing address?

Briggs's mailing address filed with the SEC is C/O REPARE THERAPEUTICS INC., , ST-LAURENT, A8, H4S 1Z9.

Insiders trading at Syndax Pharmaceuticals Inc

Over the last 9 years, insiders at Syndax Pharmaceuticals Inc have traded over $1,950,406 worth of Syndax Pharmaceuticals Inc stock and bought 210,921 units worth $2,347,816 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Luke Evnin et Briggs Morrison. On average, Syndax Pharmaceuticals Inc executives and independent directors trade stock every 50 days with the average trade being worth of $745,679. The most recent stock trade was executed by Keith A. Goldan on 14 June 2024, trading 1,250 units of SNDX stock currently worth $25,038.

What does Syndax Pharmaceuticals Inc do?

syndax pharmaceuticals is a biotechnology company located at 35 gatehouse dr., building d, floor 3, waltham, ma 02451.

Complete history of Briggs Morrison stock trades at Syndax Pharmaceuticals Inc, Arvinas Inc, Nextcure Inc, Repare Therapeutics et Codiak BioSciences

Syndax Pharmaceuticals Inc executives and stock owners

Syndax Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Michael Metzger,
  President, Chief Operating Officer, Director
• Briggs Morrison,
  Chief Executive Officer, Director
• Dr. Briggs W. Morrison M.D.,
  CEO & Director
• Michael A. Metzger M.B.A.,
  Pres, COO & Director
• Michael Meyers,
  Senior Vice President, Chief Medical Officer
• Dennis Podlesak,
  Independent Chairman of the Board
• Pierre Legault,
  Independent Director
• Keith Katkin,
  Independent Director
• William Meury,
  Independent Director
• Fabrice Egros,
  Independent Director
• Jennifer Jarrett,
  Independent Director
• Peter Ordentlich,
  Chief Scientific Officer
• Luke Albrecht,
  Senior Vice President, General Counsel, Secretary
• Daphne Karydas,
  Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, Treasurer
• Dr. Edward A. Sausville M.D., Ph.D.,
  Advisor
• Dr. Michael L. Meyers M.D., Ph.D.,
  Chief Medical Officer & Sr. VP
• Luke J. Albrecht,
  Sr. VP, Gen. Counsel & Sec.
• Alexander Nolte,
  Interim Principal Financial Officer, VP & Chief Accounting Officer
• Dr. Michael Downes Ph.D.,
  Co-Founder
• Dr. Ronald M. Evans Ph.D.,
  Co-Founder, Advisor and Chair of Scientific Advisory Board
• Dr. Richard A. Heyman Ph.D.,
  Co-Founder
• Dr. Peter Ordentlich B.Sc., Ph.D.,
  Co-Founder & Chief Scientific Officer
• Martin H. Jr. Huber,
  
• Neil Gallagher,
  President, Head of R&D
• Luke Evnin,
  Director
• Henry Chen,
  
• Partners L P/Ilbiotechnolog...,
  
• Steve M Sabus,
  Chief Commercial Officer
• Ivor Royston,
  Director
• Viii Associates, L.P.Blair ...,
  
• Vi Associates, L.P.Blair Ja...,
  
• Partners Vi, L.P.Blair Jame...,
  
• George W. Jr. Sledge,
  
• Bio Ventures Iv Qp Lp Scopa...,
  
• Partners Viii, L.P.Blair Ja...,
  
• Kim P. Kamdar,
  Director
• Richard P Shea,
  Chief Financial Officer
• Alexander Nolte,
  Chief Accounting Officer
• Catherine Madigan,
  Chief Medical Officer
• Keith A. Goldan,
  Chief Financial Officer